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A small GTPase Rho protein and an effector ROCK have signiﬁcant roles in cancer adh-
sion, metastasis, invasion, angiogenesis and cell mortality.  We investigated the expres-
sions of RhoA protein and ROCK-1 protein in 100 patients with macroscopically T3/T4 
gastric cancer immunohistochemically.  The expression of RhoA was detected in gastric 
cancer specimens from 39 patients and that of ROCK-1 in specimens from 30 patients. 
The clinicopathological characteristics of 21 tumors with co-expression of RhoA and 
ROCK-1 proteins (Rho/ROCK ON) were compared with those of the 79 remaining tu-
mors (Rho/ROCK OFF).  The percentage of lymph node metastasis positive cases in the 
Rho/ROCK ON group (81%) was higher than that in the Rho/ROCK OFF group (66%), 
but the difference was not signiﬁcant (P = 0.183).  However, the prognosis of the 21 pa-
tients with Rho/ROCK ON was signiﬁcantly poorer than that of the 79 with Rho/ROCK 
OFF (P = 0.006). Our results indicate that the evaluation of the protein expression of 
RhoA and ROCK-1 is useful for predicting the prognosis in patients with T3/T4 gastric 
cancer.
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Small GTP-binding proteins are thought to be 
involved in signal transduction pathways that 
control sets of essential cellular functions such 
as reorganization of the actin cytoskeleton, gene 
expression, cell cycle progression, and cell-cell 
adhesion (Malliri and Collard, 2003).  The small 
GTP-binding protein Rho is part of a subfamily 
of the Ras superfamily that includes Cdc42, Rac 
and Rho proteins.  The Rho family has an impor-
tant role in cancer development and progression, 
including cell-cell adhesion, cell motility, trans-
formation, proliferation, invasion, and metastasis 
(Suwa et al., 1998; Pan et al., 2004; Kamai et 
al., 2003).  Cancer cell migration is central to 
the process of metastasis.  Rearranging the actin 
cytoskeletal proteins in response to Rho is impor-
tant for the ability of tumor cells to metastasize 
(Chrzanowska-Wodnicka, 1996; Benitah et al., 
2004). Activation of Rho results in binding to 
various effector molecules that elicit downstream 
responses (Aznar, 2004).  The ROCK family, 
Rho-associated serine-threonine protein kinase, 
is one of the effector molecules of Rho.  ROCK is 
thought to participate in the induction of focal ad-
hesions and stress ﬁbers in cultured cells (Itoh et 
al., 1999).  In addition, it has been suggested that 
ROCK-1, one of the isomers of ROCK may play 
an essential role in the invasion of cancer cells 
(Kaneko et al., 2002; Yoshinaga, 2003).  Rho 
protein overexpression has been reported in the 
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progression of human cancers, suggesting that the 
Rho/ROCK pathway may be a molecular target 
for prevention of cancer invasion and metastasis 
(Sahai, 2003; Somlyo, 2003). 
 In order to elucidate the malignant potential 
of gastric cancer, multiple genetic alterations in-
cluding activation of oncogenes and inactivation 
of tumor suppressor genes have been investigated 
vigorously.  In studies on the expression levels 
of RhoA, RhoB, RhoC, Rac1, Rac2, Rac3 and 
Cdc42, increased expressions of RhoA and Rac1 
were related to a higher TNM stage and undiffer-
entiated type in gastric cancer (Pan et al., 2004). 
Accumulating clinical and experimental data sug-
gest that RhoA working through ROCK protein 
kinases contributes to the invasive and metastatic 
abilities of gastric cancer.  ROCK inhibitors, such 
as Y-27632 or WF-536, have been used in some 
studies (Takamura et al., 2001; Nakajima et al., 
2003a).  Although these inhibitors are potent and 
selective, it remains a possibility that these com-
pounds inhibit additional kinases, such as PRK/
PKN (Davies et al., 2000).  In addition, adminis-
tration of ROCK inhibitors to whole animals may 
block tumor cell invasion by enhancing the barrier 
function of host cell layers (Wojciak-Stothard et 
al., 2001; Nakajima et al., 2003b).  Furthermore, 
ROCK inhibitors would be useful antiangiogenic 
chemotherapeutic agents in tumors associated 
with elevated Rho/ROCK expression (Croft et al., 
2004).  However, Rho/ROCK expression in gas-
tric cancer and its relationship to a patient’s prog-
nosis has yet to be clariﬁed.
 Primary T3/T4 gastric cancer frequently 
metastasizes to the liver and to the peritoneum, 
and the prognosis of such cases remains unfavor-
able. In the present study, we immunohistochemi-
cally detected the protein expression of RhoA and 
ROCK-1 in patients with T3/T4 gastric cancer 
who underwent curative gastrectomy.  We also 
investigated the clinical signiﬁcance of the Rho/
ROCK pathway in advanced gastric cancer with 
special reference to the mode of recurrence and 
survival of the patients.
 
Materials and Methods
 
Patients
Primary T3/T4 gastric adenocarcinoma speci-
mens were obtained from 100 patients who under-
went curative gastrectomy at our institution from 
1976 to 1995.  The patients’ ages ranged from 31 
to 91 years (average 64.8 years); 64 were male and 
36 were female.  The clinicopathological ﬁndings 
were determined according to the Japanese Clas-
sification of Gastric Carcinoma by our hospital 
pathologists (Japanese Research Society for Gas-
tric Cancer, 1995).  All patients had undergone 
either distal, proximal or total gastrectomy with 
dissection of the level 1 and 2 regional lymph 
nodes (D2).  The patients’ follow-up periods for 
survivors ranged from 2 to 216 months (median, 
42 months) after surgery. Informed consent was 
obtained from all subjects and/or their guardians. 
Immunohistochemistry
The methods used for immunostaining for RhoA 
protein were as described previously (Horiuchi et 
al., 2003).  A streptoavidin-biotin kit (Histofine 
SAB-PO kit; Nichirei, Tokyo, Japan) was used for 
formalin-ﬁxed and parafﬁn-embedded specimens. 
Sections (4 μm in thickness) were dewaxed in 
xylene, rehydrated in ethanol and then heated in 
an autoclave oven (120˚C) for 20 min for retrieval 
of antigens. Endogenous peroxidase was blocked 
with 0.3% hydrogen peroxide in methanol for 20 
min.  Tissue sections were then washed twice 
with phosphate buffered saline (PBS) and pre-
blocked for 60 min with 10% rabbit serum.  After 
washing with PBS, the samples were incubated 
overnight at 4˚C with anti-RhoA monoclonal an-
tibody (sc-418, Santa Cruz Biotechnology, Santa 
Cruz, CA) at a dilution of 1:100.  Sections were 
then washed three times in PBS and incubated 
with the secondary anti-mouse immunoglobulin 
(IgG + IgA + IgM) conjugated with biotin for 60 
min, followed by incubation with a streptavidin-
11
Rho-ROCK expression in gastric cancer
peroxidase complex for another 60 min.  After 
three additional washes in PBS, diaminobenzidine 
tetrahydrochloride working solution was applied. 
Finally, the slides were counterstained with he-
matoxylin.  Staining for ROCK-1 was performed 
with an anti-ROCK-1 polyclonal antibody (c-19, 
Santa Cruz Biotechnology) at a dilution of 1:100, 
using a similar method to that for the RhoA stain-
ing.  RhoA and ROCK-1 expressions were not de-
tected in the non-neoplastic region of the resected 
specimens.  Expressions of RhoA and ROCK-1 
were evaluated according to the ratio of positive 
cells per specimen as described previously (Liu 
et al., 2004).  The staining pattern of RhoA or 
ROCK-1 was classiﬁed as follows: negative (nega-
tive or equivocal staining or when less than 20% 
carcinoma cells were detected) and positive (when 
20% and more carcinoma cells were detected). 
Two observers who were unaware of the clinical 
data or the disease outcome examined all of the 
histological slides.  When the interpretation dif-
fered between the two observers, a conference 
microscope was used for re-evaluation and ﬁnal 
decision. 
 
Statistical analysis
The association of factors was evaluated by the 
2-test.  The significance of difference among 
means was determined by the Mann-Whitney U 
test.  The survival rates were estimated by the 
Kaplan-Meier method, and statistical analysis was 
carried out by the log-rank test for equality of 
the survival curves.  The Cox proportional haz-
ard model and a stepwise procedure assessed the 
influence of each variable on survival.  The ac-
cepted level of signiﬁcance was P < 0.05. 
 
Results
 
RhoA/ROCK-I expression and clinicopath-
ological ﬁndings 
RhoA and ROCK-1 expressions could not be de-
tected in the non-neoplastic gastric mucosas or in 
the underlying stromal cells.  They were detected 
only in cancer cells (Fig. 1).  We decided that 39 
cases (39%) were RhoA positive and 30 cases 
(30%) were ROCK-1 positive (Table 1).  RhoA 
and ROCK-1 were co-expressed in 21%. No sig-
Fig. 1.  Immunohistochemical staining pattern of RhoA and ROCK-1 in gastric cancer.  Protein expressions of RhoA 
and ROCK-1 were detected in gastric cancer cell nuclei.  A: RhoA positive case.  B: ROCK-1 positive case.  Bar = 
100 μm (both in A and B).
A B
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Table 2.  Coexpression of RhoA and ROCK-1 proteins and clinicopathological parameters
  RhoA/ROCK-1 expression
 Both positive (n = 21) Else (n = 79) P
Size (cm) 9.0 ± 5.1 8.7 ± 4.6 0.981
Histology
 Differentiated/Undifferentiated  8/13 35/44 0.61
Mode of invasion
 Expansive/Inﬁltrative 11/10 43/36 0.867
Depth of tumor invasion
 T3/T4  20/1  74/5 0.788
Lymph node metastasis
 Negative/Positive  4/17 27/52 0.183
Lymphatic invasion
 Negative/Positive  3/18 19/60 0.337
Vascular invasion
 Negative/Positive  5/16 26/53 0.423
Histological stage
 II/III/IV  4/16/1 27/44/8 0.233
Table 3.  Correlation between RhoA/ROCK-1 protein expression and mode of recurrence
     Recurrence  pattern  RhoA/ROCK-1 expression
 Both positive (n = 21) Else (n = 79) P
Peritoneal 7 (33%) 18 (23%) 0.321
Hematogenic 5 (24%) 9 11%) 0.145
Nodal 1 ( 5%) 4 ( 5%) 0.955
Remnant stomach or others 2 ( 9%) 6 ( 8%) 0.772
Total 15 (71%) 37 (47%) 0.045
nificant correlation was detected between these 
expressions and clinicopathological parameters 
including age, sex, tumor size, histology, mode 
of invasion, lymph node metastasis, lymphatic-
vascular space invasion and histological stage (data 
not shown).
 The clinicopathological characteristics of 
21 patients with tumors co-expressing RhoA and 
ROCK-1 were compared with those of the other 
79 patients. The lymph node metastases were ob-
served in 81% of the former group in comparison 
to 66% of the latter (P = 0.183, Table 2). 
Mode of recurrence
Fifty-two patients died of gastric cancer during 
the follow-up period. Fifteen of 21 patients (71%) 
with the tumor co-expressing Rho and ROCK-1 
died, while 37 of 79 patients (47%) with the tu-
Table 1.  Correlation of RhoA and ROCK-1 ex-
pression in 100 gastric cancers
  ROCK-1 expression
 Positive  Negative  Total
RhoA expression 
    Positive 21 18   39 
    Negative 9  52   61 
Total 30  70  100 
The association of RhoA and ROCK-1 expression: P < 0.001.
mor not expressing both Rho and ROCK-1 died 
as well (P = 0.045).  Peritoneal metastatic recur-
rences were frequent in both groups. However, the 
hematogenic metastases (to liver, lung or bone) 
tend to be more frequent in patients with Rho and 
ROCK-1 co-expressing tumors (9/79 [11%], P = 
0.145, Table 3).
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Prognosis of patients
The overall 5-year survival rate of 100 patients with 
T3/T4 gastric cancer was 40%, and the disease-
speciﬁc 5-year survival rate of these patients was 
42%.  The disease-speciﬁc 5-year survival rate of 
21 patients with both RhoA- and ROCK-1-positive 
tumors (19%) was signiﬁcantly lower than that of 
the remaining 79 patients (48%, P = 0.006, Fig. 2).  
 Multivariate analysis was performed with 
the Cox proportional hazards model using the co-
variates for histological type, lymph node metas-
tasis, lymphatic invasion, venous invasion and co-
expression of RhoA and ROCK-1 (Table 4). The 
analysis revealed that lymph node metastasis and 
RhoA/ROCK-1 expression independently contrib-
uted to shortened survival.
 
Discussion
 
Rho family GTPases are key regulators of many 
different biological processes including cell motil-
ity (Etienne-Manneville and Hall, 2002; Coleman 
et al., 2002).  When bound to GTP, Rho family 
proteins recruit effector proteins that influence 
the architecture of the actin cytoskeleton.  RhoA 
and RhoC activate the serine/threonine kinases 
ROCK-1 and ROCK-2.  ROCK activation pro-
motes the stabilization of filamentous actin (F-
actin), phosphorylation of regulatory myosin light 
chains (MLCs), the increase in myosin ATPase 
activity and the coupling of actin-myosin force 
generation and contractility.  In ﬁbroblasts grown 
in tissue culture, RhoA signals through ROCK-1 
and ROCK-2 to promote the formation of stress 
ﬁbers and focal adhesions that lead to contractile 
actin-myosin bundles (Leung et al., 1996; Uehata 
et al., 1997; Riento, 2003).  Moreover, genetic 
experiments in Drosohila revealed that elevated 
Rho signaling in epithelial cells resulted in a loss 
of epithelial characteristics and increased invasive 
migratory behavior (Speck et al., 2003).  
 Co-overexpression of Rho and ROCK pro-
teins in cancer cells has been reported in ovarian 
cancer, pancreatic cancer, testicular cancer and 
bladder cancer (Suwa et al., 1998; Kamai et al., 
Fig. 2.  The disease-speciﬁc survival curves of patients 
with T3/T4 gastric cancer according to RhoA/ROCK-1 
protein expression.  The disease-speciﬁc survival curve 
of 21 patients with both RhoA- and ROCK-1-positive 
tumors (Rho/ROCK ON group) was signiﬁcantly worse 
than that of remaining 79 patients (Rho/ROCK OFF 
group, P = 0.006). 
Table 4.  Multivariate survival analysis by the Cox proportional hazards model
 
     Variables Number of patients   Hazard ratio 95% Conﬁdential interval P
Tumor histology
 Differentiated/undifferentiated 43/57 0.669 0.387 – 1.156 0.150
Lymph node metastasis
 Positive/negative 69/31 3.000 1.401 – 6.425 0.005
Lymphatic invasion
 Positive/negative 78/22 0.955 0.452 – 2.019 0.904
Vessel invasion
 Positive/negative 69/31 1.180 0.655 – 2.126 0.582
RhoA/ROCK-1 protein expression
 Both positive/else 21/79 1.836 1.033 – 3.263 0.039
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2003, 2004).  Among Rho family and ROCK pro-
teins, RhoA and ROCK-1 proteins were reported 
to play important roles in carcinogenasis, cancer 
cell adhesion, metastasis, invasion and angiogen-
esis (Itoh et al., 1999; Matsumoto et al., 2001; 
Igishi et al., 2003; Horiuchi et al., 2003; Shikada 
et al., 2003).  On the other hand, RhoB plays a 
tumor-suppressive role in human lung cancer 
(Mazieres et al., 2004).  Thus, to investigate the 
possible prognostic value, we analyzed RhoA and 
ROCK-1 protein expressions in advanced gastric 
cancer immunohistochemically. 
 In studies on gastric cancer concerning the 
expression levels of RhoA, RhoB, RhoC, Rac1, 
Rac2, Rac3 and Cdc42, increased expressions of 
RhoA and Rac1 were related to a higher TNM 
stage and undifferentiated type in gastric carcino-
ma (Pan et al., 2004).  In the current study, 21% of 
tumors were positive for both Rho and ROCK-1: 
they seemed to have a higher tendency for lymph 
node metastasis, lymphatic invasion, and vascular 
invasion.  They did not show a signiﬁcantly higher 
propensity of tumor invasion.  However, we found 
that the prognosis of double-positive patients was 
signiﬁcantly poorer than that of the other patients. 
Also, multivariate survival analysis revealed that 
the double positive tumor was an independent 
prognostic factor for advanced gastric cancer as 
well as lymph node metastasis.  To our knowl-
edge, this is the ﬁrst report to suggest that patients 
with RhoA/ROCK-1 double positive gastric can-
cer have a signiﬁcantly poor prognosis. 
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